Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 1303295
Species: Rattus norvegicus
RGD Object: Gene
Symbol: S100a11
Name: S100 calcium binding protein A11
Acc ID: CHEBI:27899
Term: cisplatin
Definition: A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID: MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
S100a11affects expressionISOS100A11 (Homo sapiens)6480464CTDCisplatin affects the expression of S100A11 mRNAPMID:23300844
S100a11increases response to substanceISOS100A11 (Homo sapiens)6480464CTDS100A11 mutant form results in increased susceptibility to CisplatinPMID:25940438
S100a11multiple interactionsISOS100A11 (Homo sapiens)6480464CTD[S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of CASP3 protein; [S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of CASP9 protein; [S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of CASP3 protein]; Acetylcysteine inhibits the reaction [[S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of CASP9 protein]; Acetylcysteine inhibits the reaction [[S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein]; S100A11 mutant form promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]; S100A11 mutant form promotes the reaction [Cisplatin results in increased expression of H2AX protein]PMID:25940438
Go Back to source page   Continue to Ontology report